STATISTICS IN MEDICINE, VOL. 2, 505–508 (1983)

AUTHOR INDEX

Albert, A., 95
Andrews, V., 87

Baretta, R., 259
Bell, C. M. J., 363
Bennett, B., 477
Bennett, S., 273
Bentley, J. M., 59
Beral, V., 455
Berry, D. A., 331
Bezemer, P. D., 191
Brambilla, P., 259
Brookmeyer, R., 485

Campbell, M. J., 223
Cates, W. Jr., 25
Chakraborty, R., 13
Chan, L. S., 447
Chiew, M. K., 79
Clark, G. M., 497
Clayton, D. G., 229
Coleman, D. A., 363

De Jonge, H., 155
Dennis, N. R., 87

Ellis, S. H., 183

Fayers, P. M., 429
Finney, D. J., 113
Fox, T. L., 331
Fraser, P., 455
Freedman, L. S., 167

Giefer, E. E., 381
Gitomer, S. L., 397
Greenland, S., 243
Green, J. R., 79
Griffiths, K., 123, 141
Grimes, D. A., 25
Groom, G. V., 123

Habbema, J. D. F., 199, 279
Hartz, A. J., 381
Haskey, J., 455
Hearne, E. M. III, 497
Hermans, J., 199
Hoffmann, R. G., 381
Hudec, M., 287

Inskip, H., 455

Jones, D. R., 183, 429

Kay, C., 123
Kay, R., 41
Kemp, K. W., 123, 141
Knox, E. G., 1
Koch, G. G., 397

Leijnse, B., 131
Low, H. C., 79
Lowe, D., 167

Macaskill, P., 167
McCabe, G. P. Jr., 417
McDonald, C. J., 417
McDowall, M., 467
McManus, I. C., 253
Machin, D., 87
Majumder, P. P., 13
Mantel, N., 259, 323, 355
Marcuson, R., 327
Marocchi, A., 259
Marubini, E., 295
Mazzuca, S. A., 417
Michalek, J. E., 315
Miettinen, O. S., 267
Mihalko, D., 315
Mocarelli, P., 259
Morabito, A., 295
Morgenstern, H., 387
Mulder, C., 191

Netelenbos, J. C., 191
Nix, A. B. J., 123, 141

Oakes, D., 305
Oler, J., 59
Olshen, R. A., 345
Oortmarssen, G. J. van, 279
Overturf, G. D., 447

Paddle, G. M., 477
Platz, H., 287
Putten, D. J. van, 279

Richards, G., 141
Rowlands, R. J., 123, 141
Rümke, C. L., 175

Schaefer, R. L., 71
Schmitz, P. I. M., 199
Schulz, K. F., 25
Schumacher, M., 41
Selik, R. M., 25
Selzer, J., 447
Siler, W., 373
Simon, S., 345
Skalland, L., 397
Spiegelhalter, D. J., 33, 207
Stokes, M. E., 397
Stovin, P. G. I., 33
Stamhuis, I. H., 191
Straub, J. P., 191

Tate, H., 217
Theune, J. A., 191
Thompson, S. G., 147
Tippett, P. A., 87
Tyler, C. W. Jr., 25

Valsecchi, M. G., 295

Weiss, K. M., 13
Whitehead, J., 183
Wilson, D. W., 123, 141
Winn, D. M., 387
Wong, M. A., 345
Woodrow, J. C., 79

SUBJECT INDEX

((L) indicates subject discussed in Letter to the Editors)

Abortion complications, 25
Abortion, Joint Program for the study of (JPSA III), 25
Adjustment for litter effects, 315, 323, 325
Adjustment of proportional mortality ratio, 467
Adjustment of rates, 455
Aetiological factors, 223
Age-adjustment of rates, 455
Age-specific rates, 455
Allocation rules, 95
Anaemia, 223
Ankylosing spondylitis, 79
Antiarrhythmic drug effect, 331
Antibody response, 447

Bias, correction in logistic regression, 71
  in cohort studies, 25
  lead time, 279
  length, 279
  overdiagnosis, 279
Bimodality, 253
Biopsy, heart muscle, 33
Blood pressure, 253
Breast Cancer Study, Health Insurance Plan (HIP study), 279
Breast Study, Manchester Regional (MRBS), 41

Cancer, breast, 41, 279, 415(L), 485
  carcinogenesis model, 363
  chemotherapy, 429
  clinical trials, 429
  death rates, 113
  lung, 183, 273
  malignant melanoma, 295
  monitoring, 217
  oral cavity, 287
  pancreas, 217
  screening, 217, 279
  treatment side effects, 429
  tumour markers, 217
Carcinoembryonic antigen, 217
Cardiac transplantation, 33
Carrier probability, 87
Case-control studies, 229, 243, 355, 477
  stratification in, 229
Censored data, 41, 273, 287, 295, 305, 315, 323, 325, 485
Cerebral palsy, 345
Change over design, clinical trial, 397
Change-point analysis, 141, 147
Classification, errors in cohort studies, 25
  recursive partitioning rule, 345
Clinical chemistry, 123, 131, 141, 417
  reference method, 131
Clinical studies, deficiencies in, 155
Clinical trials, 167, 207, 355
  antiarrhythmic drug effect, 331
  breast cancer, 41, 415(L)
  cancer, 429
  carry-over effects, 397
  change-over design, 397
  design, 175
  ethics, 175
  group sequential designs, 167
  interim analysis, 183
  missing observations, 155
  placebo effect, 417
  power, 175
  quality of life, 429
  sequential, 183
  size, 175
  stopping rules, 167
  withdrawal of patients, 155
Cluster analysis, *k*th nearest neighbour rule, 345
Coeliac disease, 79
Cohort studies, 363
  bias, 25
  misclassification, 25
  power, 25
  size, 25
Competing risks, 41, 373
Compound distribution, 253
Confounding factors, 59, 267
Contingency tables, backward elimination, 59
  collapsibility, 59
  conditional association, 79
  confounding, 59
  log-linear models, 59
  model selection, 59
Correlation between time series, 413(L)
Correlation, serial, 497
Cusum techniques, 141

Database, medical, 355
Death rates, 381
  age-adjusted, 455
  cancer, 113
  conditional, 41
  excess, 363
Decision technology, 207
Dental health, 59
  Rural study (RDHS), 59
Diagnosis, 207
  cancer, 217
  coronary heart disease, 413(L)
  laboratory reference limits, 191
  myocardial infarction, 199
  probability of particular, 87
Dioxin, 259

Discriminant analysis, 95, 199, 229
  allocation rules, dynamic prognosis, 95
  kernel method, 199
  linear, 199
  logistic, 199
  quadratic, 199
Disease recurrence, analysis of, 41
  model of manifestation, 13
Drug evaluation, 155
Drug registration, 155
Drug treatment, 417
Duchenne muscular dystrophy, 87
Dyspepsia, 207
  Glasgow system, 207
Distributions, bimodal, 253
  survival, 305

Efficacy of treatment, 267
EM algorithm, 33
Environmental risk factors, 13
Environmental stress, 373
Epidemic, 1
Epidemiology, 25, 147, 223, 267, 355, 387
  genetic, 13
  interactions, 243, 355
  perinatal, 229
  prenatal infections, 1
Error rates, 33, 95
Ethics of clinical trials, 175
Exercise stress testing, 327

Familial risk factors, 13
Fluoridation of water, 113
Follow-up surveys, 223

Gait measurements, 345
Generalized linear models, 223
Genetic counselling, 87
Genetic epidemiology, 13
Genstat statistical package, 223
Girshick–Rubin test, 141
Glucose challenge, 95
Group selection, Morgan–Sonquist procedure, 295
Group sequential designs, clinical trials, 167

Hazard functions, 41, 305, 373
  convergent, 273
Hazards model, proportional, 183, 287
Hazards, occupational, 477
Heartburn, 397
Heart disease, coronary, 413(L)
  ischaemic, 147, 477
Heart muscle biopsy, 33
Heart study, Northwick Park (NPHS), 147
Heart transplantation, 33
HLA antigens, 79

Immunity, 1
Incomplete penetrance of genes, 13
Industrial chemicals and health, 477
Information systems, medical, 207
Interactions in epidemiological studies, 243, 355
Interim analysis in clinical trials, 183
International Society for Clinical Biostatistics (ISCB),
  Third International Conference, Rotterdam,
    committees, 111
    keynote lecture, 113
    papers from, 113–311
Intraventricular haemorrhage, 167
Ischaemic heart disease, 147, 477

Karnofsky scale, 429

Laboratory determinations, multivariate analysis of, 259
  percentiles, 191
  reference values, 191
  time trends in, 147
Laboratory monitoring, 123, 131, 141
Law, medicine and, 113
Litter effects, adjustment for, 315, 323, 325
Logistic discrimination, 199
Logistic model, 79
Logistic regression, 71, 223
Logistic transformation, 79
Log-linear models, 59, 229
Logrank scores, 315
Logrank test, 183

Mantel–Ciminera procedure, 315, 323, 325
Mantel–Haenszel procedure, 259, 315
Maximum likelihood fitting, 71, 253
Medical databases, 355
Medicine and law, 113
Misclassification in cohort studies, 25
Missing observations in clinical trials, 155
Model, accelerated failure time, 287
  carcinogenesis, 363
  competing risks, 41, 373
  Cox regression, 183
  generalized linear, 223
  logistic, 79
  log-linear, 59, 229
  maximum-likelihood fitting, 71, 253
  of disease manifestation, 13
  of prenatal infection, 1
  proportional hazards, 183, 287
  proportional odds, 273
  selection in contingency tables, 59
  survival, 41, 287, 305, 373
Monitoring, cancer, 217
  laboratory, 123, 131, 141
Morgan–Sonquist procedure, 295
Mortality, 373, 381
  case, 279
  index, 455
  occupational, 381, 467
  perinatal, 229

Mortality ratio, proportional, 455, 467
  standardized, 363
Multivariate analysis, cluster analysis, 345
  discriminant analysis, 95, 199, 229
  of laboratory determinations, 259
Multivariate permutation test, 327
Multivariate response curve, 95
Muscular dystrophy, Duchenne, 87
Myocardial infarction, 95, 199
  Rotterdam Study of Imminent (IMIR), 199

Nearest neighbour rule, 345

Occupational hazards, 363, 477
Occupational mortality, 381, 467
Odds ratio, 243, 273, 455

Pancuronium bromide, 167
Percentiles for laboratory determinations, 191
Perinatal mortality study, Leicestershire, 229
Permutation test, multivariate, 327
Placebo effect, 417
Power of clinical trials, 175
  cohort studies, 25
  sphericity test, 497
  tests of interaction in epidemiology, 243
Power station employees, 477
Prediction intervals for survival times, 485
Prenatal infection, 1
Preterm infants, 167
Progesterone assay, 123, 141
Prognostic factors, 223, 295
Proportional hazards model, 183, 287
Proportional mortality ratio, 455, 467
Proportional odds model, 273

Quality assessment scheme, National External, 123
Quality control, 123, 131, 141, 147
  programme, Dutch, 131
Quality of life in cancer clinical trials,
  measurement and analysis, 429
Quantiles, prediction intervals for, 485

Randomization, 267
Rank tests, linear, 315
Rates, age adjusted, 455
Reference method in clinical chemistry, 131
Reference values for laboratory determinations, 191
Registration of drugs, 155
Regression, Cox model, 183
  logistic, 71, 223
  models, survival data, 287, 305
  multiple linear, 331
  to the mean, 253, 417
Relative risk, 13, 25, 243, 455
Renal transplantation, 295
Repeated measures design, 497

Response curve, multivariate, 95
Risk factors, 71, 223, 229, 243, 477
  environmental, 13
  familial, 13
Risk index for myocardial infarction, 95
Rubella, 1

Sample size, clinical trials, 175
  cohort studies, 25
  epidemiological studies, 387
  reference limits, 191
Sampling ratio, 387
Screening, cancer, 217
  mass, 279
Sequential analysis, 183
Serial correlation, 497
Serial dilution methods, 447
Serology, 447
Seveso disaster, 259
Shewhart chart, 141
Shewhart's principle, 131
Significance tests, 113
Size of clinical trials, 175
  cohort studies, 25
  epidemiological studies, 387
Sphericity, validity and power of test of, 497
Sporadics, 13
Standardization, 455
Stopping rules for clinical trials, 167
Surveys, follow-up, 223
Survival analysis, 41, 183, 273, 279, 287, 295, 305,
    315, 327, 373, 415(L), 485
Survival, disease-free, 41
Survival distributions, 305
Survival times, prediction intervals for, 485

Therapeutic equivalence, 167
Thyrotoxicosis, 79
Time series, correlation between, 413(L)
Time trends in laboratory determinations, 147
Tissue rejection, 33
Toxicity of treatment, 267
Transformation, logistic, 79
Transplantation, heart, 33
  renal, 295
Treatment efficacy, 267
  toxicity, 267
Tumour markers, 217

Vaccination programmes, 1
Vaccine studies, 447
Variables, mixture of, 199
Ventricular contraction, premature, 331

Water fluoridation, 113
Witness, expert statistical, 113